Melanoma & Skin Cancer – Medical News Asia

U.S.-FDA-approved-immunecheckpoint-inhibitors-e1528902398517

US FDA approved immune-checkpoint inhibitors updated 08-Dec-2020

8 December 2020/19 Comments/in Gastrointestinal Cancer, Genitourinary Cancer, Gynaecological Cancer, Haematology, Head and Neck Cancer, Lung Cancer, Oncology, Melanoma & Skin Cancer, Immunotherapy, AE Management, irAE Management/by Stijn van den Borne, MSc

Know all the United States Food and Drug Administration (U.S. FDA) approved immune-checkpoint inhibitors. Members of MediPaper can download the free PPT slides summarising the U.S. FDA approved immune-checkpoint inhibitors and other U.S. FDA approved immunotherapies.

Case sharing – use of avelumab in Merkel cell carcinoma

8 March 2019/Enter your password to view comments./in Oncology, Melanoma & Skin Cancer, Immunotherapy/by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

Pembrolizumab FDA approved for adjuvant treatment of melanoma

16 February 2019/0 Comments/in US FDA Onc\Haem Approvals, Oncology, Melanoma & Skin Cancer, Immunotherapy, Surgery/by scienterrific

On 15 February 2019, the FDA approved pembrolizumab (Keytruda®, Merck) for the adjuvant treatment of melanoma patients with lymph node involvement following complete resection.

Keytruda® FDA approved for recurrent and metastatic Merkel cell carcinoma

14 January 2019/0 Comments/in US FDA Onc\Haem Approvals, Oncology, Melanoma & Skin Cancer, Immunotherapy/by Stijn van den Borne, MSc

On 19 December 2018, pembrolizumab (Keytruda®, Merck) received accelerated approval by the FDA for the treatment of recurrent locally advanced or metastatic (R/M) Merkel cell carcinoma (MCC) in adult and paediatric patients.

PD-1 mAB cemiplimab FDA approved for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC)

3 October 2018/1 Comment/in US FDA Onc\Haem Approvals, Oncology, Melanoma & Skin Cancer, Immunotherapy/by scienterrific

On September 28, 2018, the FDA approved programmed death 1 (PD-1) immune-checkpoint inhibitor cemiplimab-rwlc (Libtayo®, Regeneron) for use in patients with metastatic cutaneous squamous cell carcinoma (CSCC) and patients with locally advanced CSCC unamenable for curative surgery or curative radiation.

First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

22 August 2018/0 Comments/in Breast Cancer, Medical News Asia, Genitourinary Cancer, Lung Cancer, Melanoma & Skin Cancer, Oncology, Immunotherapy, Translational Research/by scienterrific

Biosceptre has announced the initiation of its Phase 1 clinical study with the peptide vaccine BIL06v. BIL06v is a peptide-protein conjugate that recruits the patient’s immune system to make antibodies specifically targeted at nfP2X7-expressing cancer cells resulting in tumour cell death.

Anti-PD1 with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

26 July 2018/0 Comments/in Oncology, Melanoma & Skin Cancer, Immunotherapy/by scienterrific

Programmed death 1 (PD-1) inhibition with the novel human anti-PD1 monoclonal antibody cemiplimab (REGN2810, Regeneron and Sanofi) in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma (CSCC) resulted in a response in approximately half of the patients.

Adjuvant dabrafenib plus trametinib FDA approved for BRAF V600E or V600K melanoma

30 April 2018/0 Comments/in US FDA Onc\Haem Approvals, Haematology, Oncology, Melanoma & Skin Cancer/by scienterrific

The FDA granted regular approval to dabrafenib (Tafinlar®, Novartis) and trametinib (Mekinist®, Novartis) in combination for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.